Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 15/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.71 |
| ▸ | ADRA2C | P18825 | 5/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.71 |
| ▸ | RECQL | P46063 | 1/20 | 0.71 |
| ▸ | BLM | P54132 | 1/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | DRD1 | P21728 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.68 |
| ▸ | HTR1D | P28221 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.68 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7124492 | 0.87 | KDM1A (0.79) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7124493 | 0.86 | KDM1A (0.77) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7121656 | 0.84 | KDM1A (1.00) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL1664525 | 0.83 | KDM1A (1.00) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7122730 | 0.81 | KDM1A (0.72) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL27965099 | 0.80 | ADRB1 (0.68) | KDM1ATDP1ADRB2SLC6A2HTR7 | |
| SCHEMBL7118679 | 0.80 | KDM1A (0.70) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7126115 | 0.80 | KDM1A (0.74) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL7124431 | 0.79 | KDM1A (0.73) | KDM1AADRA2AADRA2CADRA2BGLA | |
| SCHEMBL14389067 | 0.79 | KDM1A (0.84) | KDM1AADRA2AADRA2CADRA2BGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183912-B2 | HDMX inhibitors and their use for cancer treatment | MiRx Pharmaceuticals, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MIRX PHARMACEUTICALS LLC (US) | 2017-01-26 | — | — | US | disclosed |
| WO-2015153535-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | MiRx Pharmaceuticals, LLC (US) | 2015-10-08 | — | — | WO | disclosed |
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ORION CORPORATION | 2003-12-04 | — | — | US | disclosed |
| US-6593324-B2 | P-aminoanilino- derivatives | ORION CORPORATION (FI) | 2003-07-15 | — | — | US | disclosed |
| EP-1263733-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION FARMOS (FI) | 2002-12-11 | — | — | EP | disclosed |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | OY JUVANTIA PHARMA LTD. (FI) | 2001-11-29 | — | — | US | disclosed |
| WO-2001064645-A2 | DERIVATIVES OF QUINOLINE AS ALPHA-2 ANTAGONISTS | ORION CORPORATION (FI) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022166-A1 | NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT | TP53, DDX3X, API5 | KDM1A 702/4885ADRA2A 4844/4885ADRA2C 4837/4885 |
| US-20030225078-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | KDM1A 1512/4885ADRA2A 2/4885ADRA2C 6/4885 |
| US-10183912-B2 | HDMX inhibitors and their use for cancer treatment | TP53, MDM4, MDM2 | KDM1A 650/4885ADRA2A 4833/4885ADRA2C 4834/4885 |
| US-20010046991-A1 | Derivatives of quinoline as alpha-2 antagonists | ADRB2, ADRA2A, ADRB1 | KDM1A 1512/4885ADRA2A 2/4885ADRA2C 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.